The promise is not just a number, but a map. For a growing cohort of health-conscious consumers, the question is no longer just "How old am I?" but "Which parts of me are aging fastest?" Liv Longevity Labs, a Berlin-based startup founded in 2024, is building its direct-to-consumer business on that precise distinction. Its core product translates a single at-home blood test into a personalized dashboard showing a user's overall biological age, their speed of aging, and crucially, the estimated age of 11 separate organ systems [liv.health, retrieved 2024]. At €499 per year, the service represents a significant consumer commitment, backed by a 90-day "Clear Plan Guarantee" and the integration of wearable data [liv.health, retrieved 2024]. It is a bet that individuals will invest in a quantified, systemic view of their own aging process, long before any clinical symptoms appear.
The Science Behind the Speedometer
Liv's credibility hinges on its choice of biomarkers, which it sources from a third-party lab rather than developing in-house. The company's analysis is "powered by TruAge® by TruDiagnostic" and incorporates three specific, peer-reviewed epigenetic clocks [liv.health, retrieved 2024]. Each serves a distinct purpose in constructing the user's aging profile.
- DunedinPACE. Developed from a longitudinal study tracking 1,037 people, this algorithm estimates the pace, or speed, of biological aging from a blood sample [TruDiagnostic, retrieved 2026]. It answers the question: are you aging faster or slower than your chronological years?
- SYMPHONYAge. Built by researchers at Yale and Altos Labs, this model attempts to disaggregate the aging process, providing estimated ages for 11 different organ systems, such as the heart, brain, and liver, from the same single blood draw [TruDiagnostic, retrieved 2026].
- OMICmAge. A biological age estimator developed by Harvard and Yale, validated on a combined cohort of over 60,000 individuals, which provides a single composite biological age figure [TruDiagnostic, retrieved 2026].
By licensing these established clocks, Liv sidesteps the decade-long clinical validation process. Its innovation lies in the consumer-facing packaging: a unified platform that collects the blood sample at home, integrates supplemental data from wearables, and delivers the complex results through a simplified interface with a personalized health plan.
The Direct-to-Consumer Longevity Wedge
The company's model is a classic DTC healthtech play, but applied to a nascent and scientifically complex category. The €499 annual fee positions it as a premium wellness subscription, far above the cost of a standard fitness tracker but below the price of comprehensive, physician-ordered advanced testing. The included 90-day guarantee acts as a risk-reducer for the customer, acknowledging the behavioral change required to see movement in the biomarkers [liv.health, retrieved 2024]. The business appears to be pre-revenue and in its earliest stages, with a pre-seed funding history that includes a recorded round of $2.55 million in May 2022 and smaller injections through 2024 and 2026 [Wellfound, May 2022] [LinkedIn, retrieved 2026]. While the founding team is not detailed in public records, LinkedIn profiles list a Chief Medical Officer and a Chief Scientific Officer, suggesting a clinical and research-heavy foundation [LinkedIn, retrieved 2026].
Navigating a Crowded and Unregulated Landscape
The ambition is clear, but the path is fraught with challenges common to the consumer longevity space. Liv operates in a regulatory gray area. The epigenetic clocks it uses are tools for measurement and estimation, not FDA-cleared or CE-marked diagnostics for any specific disease. The company must therefore walk a fine line: providing insightful health data without making unsubstantiated medical claims. Furthermore, the market is becoming crowded with startups offering various forms of biological age testing, from saliva-based DNA methylation kits to more comprehensive blood panels. Liv's differentiation rests on the organ-system specificity of SYMPHONYAge and the integration of its results into a longitudinal plan, but it must constantly educate consumers on why its particular suite of clocks is worth the premium.
Another significant question is clinical utility. For the concerned but otherwise healthy individual, what is the actionable outcome of learning their heart is five years older than their calendar age? The personalized health plan is Liv's answer, but the efficacy of generic lifestyle recommendations (e.g., improved sleep, nutrition, exercise) in moving these specific epigenetic markers requires more long-term, individualized data. The company's success depends on demonstrating not just measurement, but meaningful, trackable improvement for its subscribers over time.
For now, the patient population is the proactive, bio-curious consumer, typically without a diagnosed condition, who is motivated by prevention and optimization. The standard of care they are opting out of is essentially nothing; routine primary care does not yet include epigenetic profiling or multi-organ biological age assessments. These individuals are seeking earlier, more granular signals than annual physicals can provide, betting that early insight can inform interventions that delay age-related decline. Liv Longevity Labs is betting it can be the trusted guide for that journey, translating complex peer-reviewed science into a private, annual health audit.
Sources
- [liv.health, retrieved 2024] Know how fast you’re really aging | Liv Longevity Labs | https://www.liv.health/en
- [TruDiagnostic, retrieved 2026] About TruAge | https://www.trudiagnostic.com/about-truage
- [Wellfound, May 2022] Liv Longevity Labs funding | https://wellfound.com/company/liv-longevity-labs
- [LinkedIn, retrieved 2026] Amer Hamzeh - CEO & Co-Founder at Liv | https://www.linkedin.com/in/amerhamzeh/
- [LinkedIn, retrieved 2026] Vassily Eliopoulos M.D. - Chief Medical Officer & Co-Founder | https://www.linkedin.com/in/vassily-eliopoulos-m-d-5b8015143/
- [LinkedIn, retrieved 2026] Rateb El Kurd - Procter & Gamble | https://ca.linkedin.com/in/ratebelkurd
- [LinkedIn, retrieved 2026] Dr. Olena Husak - Co-Founder / CSO - Liv Longevity Labs | https://de.linkedin.com/in/dr-olena-husak-b2379166